July 23rd 2025
Emerging therapies, including antibody-drug conjugates and biomarker-driven approaches, have the potential to significantly impact outcomes for patients with traditionally poor prognoses and limited options.
The Economics of Transthyretin-Mediated Amyloidosis: Balancing Equity and Access in Resource Allocation
Advancing Immunotherapy in Endometrial Cancer: A Managed Care Perspective on Personalized Care
A Breast Cancer Risk Assessment Tool That Includes Breast Density Measures
Distinct Molecular Tumor Profile in Younger CRC Patients Recognized
Dr Ira Klein Discusses the Use of Fee-for-Service in Oncology